Abstract P4-08-05: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years
Martin Filipits(University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Ralf Kronenwett(Beth Israel Deaconess Medical Center), Florian Fitzal, P Dubsky, Ryan Bernhisel(Myriad Genetics), Richard Greil(Paracelsus Medical University), Jonathan Lancaster(Statistics Austria), CF Singer(Innsbruck Medical University), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group), M. Rudas(Comprehensive Cancer Center Vienna), M. Balic(Innsbruck Medical University)
Cited by 2
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k